Skip to main content
EU-Startups Funding· David Cendon Garcia·· 5 days agoTop DealsAI Score65

Orakl Oncology raises €30M Series A to predict cancer drug trial outcomes with AI

Can AI predict which cancer drugs will actually work? Orakl Oncology raises €30 million to find out

AI Overview

Orakl Oncology, a French TechBio spun out of the Gustave Roussy Institute, raised a €30M ($34M) Series A co-led by Norrsken VC and Singular.

Why it matters

The round shows investors backing a platform that pairs patient-derived tumor organoids with AI to forecast trial outcomes, a concrete bet on cutting late-stage oncology failure.

Source:EU-Startups Funding · eu-startups.com

Subscribe to the newsletters

Free, by email. No account needed. Pick one or both.

No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.

Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing